Nurix Therapeutics
Price & Volume
Stats
See more52W Range | $12.43-$28.23 |
Market Cap | $1.7B |
Shares Short | 18M |
Financials
See moreRevenue (12 Mos) | $701.9M |
Revenue Growth (YoY) | 8,426.3% |
Gross Profit (12 Mos) | $367.8M |
Diluted EPS | $2.43 |
News
See moreYahoo Finance • 8 days ago
Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
Yahoo Finance • 10 days ago
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
Yahoo Finance • 11 days ago
At a glance: stocks gapping down premarket
Yahoo Finance • 11 days ago
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
About
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Address | 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 317 |